Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 50.12M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.39
x | P/E ratio 2025 * |
-2.24
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.57% |
Latest transcript on Novus Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 20-04-30 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 21-03-14 |
Steven N. Perrin
PSD | President | 59 | 20-09-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 17-04-30 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 20-09-13 |
John S. McBride
BRD | Director/Board Member | 72 | 17-04-30 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |